Home

(Reuters) - U.S. health regulators said on Tuesday they received a report of a multiple sclerosis patient who died within 24 hours of taking the first dose of Novartis AG's Gilenya.

The U.S. Food and Drug Administration said at this time, it cannot conclude whether the drug, a potential blockbuster, resulted in the patient's death, but was ...

Seven-time Grand Slam champion Venus Williams has pulled out of an Australian Open warm-up tournament in New Zealand as she continues to battle a debilitating illness.

Williams is suffering from Sjogren's syndrome, an autoimmune disease, and after playing a number of recent exhibition matches she announced Tuesday she was not ready to play in the Auckland Classic, which starts ...

ZURICH (Reuters) - A third late-stage trial of Novartis' multiple sclerosis drug Gilenya did not throw up any new safety issues with the pill, going some way to alleviating concerns about possible risks linked to the potential blockbuster.

The study results come just days after Novartis said it was looking into whether the pill had caused the death of a 59-year-old ...

A new vaccine-like therapy that summons a host of antibodies to fight lupus has shown promise in early European trials, researchers said at a US conference on Tuesday.

There are very few options for treating the potentially fatal disease in which the body's immune system is overactive and attacks healthy tissue, causing fatigue, swelling, ulcers, chest pain, organ and ...

LONDON (Reuters) - Britain's highest court upheld a patent on Wednesday on a gene sequence held by Human Genome Sciences related to its new lupus drug Benlysta, in a defeat for rival drugmaker Eli Lilly.

The UK Supreme Court ruling chimes with similar support for the patent by the European Patent Office (EPO) and overturns earlier British court decisions in ...

ZURICH (Reuters) - Novartis said its drug AIN457 helped alleviate the symptoms of people suffering from moderate-to-severe plaque psoriasis, the Swiss firm said on Monday based on the results of a mid-stage study.

Plaque psoriasis is a common hereditary, immune-mediated systemic disorder characterized by skin lesions, called plaques, which can be painful.

In one study, 81 percent of patients receiving 150mg ...

PARIS (Reuters) - French drugmaker Sanofi said on Saturday that its experimental multiple sclerosis drug Lemtrada worked better than an older drug sold by competitor Merck KGaA at keeping patients free from relapses.

New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free for two years, compared with 59 percent using Rebif, an older ...

(Reuters) - Full data from a late-stage clinical trial of Biogen Idec Inc's experimental multiple sclerosis drug, BG-12, showed robust results across multiple measures and revealed no new safety concerns.

The news sent the biotech company's shares soaring as much as 6.7 percent on Friday.

Earlier this year the company released initial data from the trial, known as ...

(Reuters) - U.S. regulators have extended their review of Biogen Idec Inc's application to update the prescribing information for its multiple sclerosis drug Tysabri, the company said on Thursday.

Biogen, which sells the drug with Irish drugmaker Elan Corp Plc, is seeking to add information to the drug's label to show that measuring a patient's antibodies to ...

ZURICH (Reuters) - Swiss drugmaker Roche Holding said a mid-phase study found its ocrelizumab drug maintained significant reduction in disease activity for multiple sclerosis patients for almost two years, boosting its chances of success in late-stage trials.

"The study showed that the significant reduction in disease activity as measured by the total number of active brain lesions and relapses previously reported ...